Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABM-1310 in BRAF V600-Mutant Advanced Solid Tumors
NCT05501912Phase 1Terminated
- Sponsor
- ABM Therapeutics
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abm-1310 in solid tumor (advanced stage), intracranial tumor and brain metastases, sponsored by ABM Therapeutics. Primary endpoints: Maximum Tolerated Dose up to 33 days, Recommended Phase 2 Dose up to 33 days and 3 more. Started Sep 2022; status: terminated.
02
Drugs
abm-1310
03
Conditions
solid tumor (advanced stage)intracranial tumorbrain metastases
Beyond the preview
Go deeper on NCT05501912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501912.